Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer

Clinical Breast Cancer

Volumn 11, Issue 5, 2011, Pages 297-305

  Yardley, Denise A ^a,b   Raefsky, Eric ^b   Castillo, Raul ^c   Lahiry, Anup ^d   LoCicero, Richard ^d   Thompson, Dana ^b   Shastry, Mythili ^a   Burris, Howard A ^a,b   Hainsworth, John D ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^d Northeast Georgia Medical Center   (United States)

Author keywords

Neoadjuvant treatment

Indexed keywords

ANTIESTROGEN; BEVACIZUMAB; CARBOPLATIN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB; 130 NM ALBUMIN BOUND PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MASTECTOMY; MULTICENTER STUDY; NEUROPATHY; ONCOGENE NEU; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; PROTEINURIA; SIDE EFFECT; SURGICAL INFECTION; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; WOUND HEALING IMPAIRMENT; ADJUVANT THERAPY; BREAST TUMOR; CLINICAL TRIAL; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ALBUMINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PACLITAXEL; RECEPTOR, ERBB-2; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855725650     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.04.002     Document Type: Article

References (39)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 267285.
2. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-84. (Pubitemid 28455101)
3. Bear HD. Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 1998; 25: 3-12. (Pubitemid 28188638)
4. Sachelarie I, Grossbard ML, Chadha M, et al. Primary systemic therapy of breast cancer. Oncologist 2006; 11: 574-89. (Pubitemid 43967613)
5. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst 2001; 30: 96.
6. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100. (Pubitemid 28041584)
7. Calaris G, Berger C, Descamps P, et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 1994; 74: 1283-8. (Pubitemid 24301781)
8. Buchholz T, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute Conference. J Clin Oncol 2008; 26: 791-7. (Pubitemid 351265334)
9. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer. pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008; 26: 814-9. (Pubitemid 351265335)
10. Fisher B, Mamounas EP. Preoperative chemotherapy. a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995; 13: 537-40.
11. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-27. (Pubitemid 46622110)
12. Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009; 27: 4693-700.
13. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24: 1831-8. (Pubitemid 46638980)
14. Coudert BP, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007; 25: 2678-84. (Pubitemid 47123173)
15. Coudert BP, Arnould L, Moreau L, et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006; 17: 409-14. (Pubitemid 43329576)
16. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy. results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-85.
17. Dawood S, Gonzalez-Angulo AM, Peintinger F, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D. Anderson experience. Cancer 2007; 110: 1195-200. (Pubitemid 47435588)
18. Chang HR, Slamon D, Pratt R, et al. A phase II study of neoadjuvant docetaxel/ carboplatin with or without trastuzumab in locally advanced breast cancer. Response and cardiotoxicity. J Clin Oncol 2006; 24: 569s.
19. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
20. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-9. (Pubitemid 46224178)
21. Brufsky A, Bondarenko I, Smirnov V, et al. RIBBON-2. A randomized, doubleblind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metatastic breast cancer. Cancer Res 2009; 69: 495s.
22. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metatastic breast cancer (mBC). AVADO. J Clin Oncol 2008; 26: 43s.
23. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1. Randomized double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metatastic breast cancer (MBC). J Clin Oncol 2009; 27: 42s.
24. du Manoir JM, Francia G, Man S, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006; 12: 904-16. (Pubitemid 43259873)
25. Pegram M. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endotholial growth factor (VEGF). Breast Cancer Res Treat 2004; 88: S124.
26. Hurwitz SA, Pegram MD, Lin L-S, et al. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first-line treatment of HER2-amplified advanced breast cancer. Cancer Res 2009; 69: 854s.
27. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786-92. (Pubitemid 46630577)
28. Pegram M, Konecny G, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739.
29. Burris H 3rd, Yardley D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004; 22: 1621-9. (Pubitemid 41079800)
30. Ruiz M, Salvador J, Bayo J, et al. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62: 1085-90.
31. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759-69. (Pubitemid 38771821)
32. Slamon D, Eirmann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by trastuzumab (AC TH) with docetaxel, carboplatin, and trastuzumab (TCH) in Her2neu positive early breast cancer patients. BCIRG 006 study. Cancer Res 2009; 69: 500s.
33. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-7803. (Pubitemid 46657376)
34. Gradishar W, Krasnojon D, Cheporov S, et al. Randomized comparison of weekly or every-3 weeks (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metatastic breast cancer (MBC). J Clin Oncol 2007; 25: 40s.
35. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 3611-9.
36. Dranitsaris G, Coleman R, Gradishar W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metatastic breast cancer: an economic anlaysis of a prospective randomized trial. Breast Cancer Res 2010; 119: 717-724.
37. Okines A, Puerto OD, Cunningham D, et al. Surgery with curative intent in patients treated with first-line chemotherapy plus bevacizumab for metatstatic colorectal cancer. First BEAT and the randomized phase III N016966 trial. Br J Cancer 2009; 101: 1033-1038.
38. D'Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a match casecontrol study. Ann Surg Oncol 2007; 14: 759-765. (Pubitemid 46175324)
39. Golshan M, Garber J, Gelman R, et al. Surgical complication and the use of bevacizumab. Cancer Res 2009; 69: 496s.